Views & Analysis | Perspectives on pharma industry issues

R&D

Changing Faces: Board of Directors, January 2026

January was a relatively quiet month for Board news, but there were some notable moves here and there.

Sales & Marketing

virtual electronic medical record interface

5 forces reshaping pharma commercialisation in 2026

As infrastructure bottlenecks ease and regulatory frameworks mature, pharma's AI adoption is shifting from proof-of-concept to production-grade deployment

Digital

Five types of recruit - skill set to include for soft skills

The evolution of leadership for healthcare organisations in ...

Leaders must be adaptive, forward-thinking, and equipped to cultivate environments where humans and AI work together effectively and ethically.

R&D

JPM2026 wrap-up with Nicole Raleigh and Jonah Comstock

On JPM2026 and healthcare investment today, with Jonah Comst...

Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.

Digital

Tel Aviv Sourasky Medical Center helipad and The Jerusalem Press Club

Israel’s MedTech and health innovation landscape: Part one –...

Part One of a series of articles – Israel’s MedTech and health innovation landscape: From Tel Aviv to Jerusalem - looking at resilient progress there.

R&D

pharmaphorum podcast Episode 188a - Novo Nordisk and Veeva

Maximising value by uniting the digital backbone: On a new N...

Novo Nordisk and Veeva have entered into a new partnership for clinical development.

Market Access

Interview at BIO 2025 with Kyle Touchstone and Laura Rowley

Biotech opportunities in North Carolina, with Kyle Touchston...

From BIO 2025: Kyle Touchstone, director of Economic Development Raleigh and Laura Rowley, director of life sciences development for NCBiotech.

R&D

Changing Faces – Pharma and biotech hires – May 2025

The pharmaceutical and biotechnology sectors witnessed significant leadership changes this month, with numerous high-profile appointments spanning from established commercial-stage companie

Sales & Marketing

5 forces reshaping pharma commercialisation in 2026

As infrastructure bottlenecks ease and regulatory frameworks mature, pharma's AI adoption is shifting from proof-of-concept to production-grade deployment

Sales & Marketing

Swiss train speeding across bridge against landscape background

A fast start to 2026 signals continued investor confidence i...

Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.

Digital

The evolution of leadership for healthcare organisations in ...

Leaders must be adaptive, forward-thinking, and equipped to cultivate environments where humans and AI work together effectively and ethically.

Digital

Israel’s MedTech and health innovation landscape: Part one –...

Part One of a series of articles – Israel’s MedTech and health innovation landscape: From Tel Aviv to Jerusalem - looking at resilient progress there.

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Market Access

European biopharma at a crossroads

If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Oncology

Improving breast cancer outcomes in sub-Saharan Africa

New funding from The Pfizer Foundation will support breast cancer efforts in Kenya by the Academic Model Providing Access to Healthcare (AMPATH).

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone